1). Mechanisms of antibody-mediated antitumor immunity
2). Regulation of myeloid cell effector function
3). Expanding the therapeutic window of immunomodulatory antibodies
4). Translating myeloid-targeted therapies into the clinic
The Osorio laboratory investigates the mechanisms of antibody-mediated immunity and leverages these insights to develop more effective cancer immunotherapies. A central focus of our work is the myeloid compartment—including macrophages, dendritic cells, and related innate immune populations—and its role in orchestrating antitumor responses. We study how therapeutic antibodies engage Fcγ receptors (FcγRs) to reprogram myeloid cell function, enhance tumor cell clearance, and promote the priming and persistence of adaptive immunity. In parallel, we examine how antibody structure and format—including Fc engineering, bispecific antibodies, antibody–drug conjugates, and immune complex formation—shape these processes within the tumor microenvironment.
Using integrated approaches that combine humanized mouse models, ex vivo human systems, and high-dimensional immune profiling, we define the cellular and molecular ecosystems that govern response or resistance to therapy. Our goal is to establish mechanistic principles that guide the rational design and optimization of next-generation antibody therapeutics, enabling coordinated engagement of innate and adaptive immunity and ultimately delivering more durable clinical benefit across diverse malignancies.
Using integrated approaches that combine humanized mouse models, ex vivo human systems, and high-dimensional immune profiling, we dissect the cellular ecosystems that determine response or resistance to therapy. Our work aims to uncover principles that guide the rational design of antibody-based therapeutics capable of overcoming immune suppression, engaging innate and adaptive immunity in concert, and delivering durable clinical benefit across a range of malignancies.
Figure 1
Biography
Dr. Juan C. Osorio, MD, is a medical oncologist and Assistant Member in the Immuno-Oncology Program at Memorial Sloan Kettering Cancer Center. He also serves as Assistant Professor of Immunology and Microbial Pathogenesis at Weill Cornell Medicine and as a visiting Assistant Professor at Rockefeller University. Dr. Osorio earned his MD from the National University of Colombia, completed his internal medicine residency at NewYork-Presbyterian/Weill Cornell Medicine, and pursued a Medical Oncology fellowship at MSK. He subsequently trained as a postdoctoral fellow under Dr. Jeffrey Ravetch at Rockefeller, where he specialized in antibody biology and immunotherapy research.
